Kiora Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Mar 30, 2016 and accepted by EDGAR at Mar 30, 2016, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2015-01-01 to 2015-12-31 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months2015-01-01 to 2015-12-31 | $1.9m | us-gaap:InterestExpense |
| Net income | 12 months2015-01-01 to 2015-12-31 | −$8.4m | us-gaap:ProfitLoss |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | −$2.70 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | −$4.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | At period end2015-12-31 | $8.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $9.5m | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $3.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2015-12-31 | $6.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-16-091485. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.